NAD+ therapy cost: what to expect, and how to evaluate any quote
What we evaluated: publicly advertised pricing for NAD+ therapy across telehealth and longevity providers
Date verified: July 12, 2026
Direct answer: We do not publish a price for this treatment, because we have not verified one. Advertised figures vary enormously across telehealth and longevity clinics, and we have not captured and dated them against provider sources under our pricing-verification methodology.
Necessary qualification: Publishing an unverified number would be worse than publishing none. When we have captured these prices they will appear here with a source and a verification date, exactly as our GLP-1 pricing does. Until then, this page tells you what to ask rather than what to pay.
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
How NAD+ therapy differs from the alternatives
NAD+ is not a peptide, and it is not like the others on this site. Sermorelin and tesamorelin are GHRH analogues that act on the pituitary. NAD+ is a coenzyme — a small molecule present in every living cell, central to mitochondrial energy production and to sirtuin and PARP enzyme activity.
That difference matters for how you should read the evidence. With the GHRH peptides, the mechanism is demonstrable and the outcome evidence is weak. With NAD+, the underlying cell biology is genuinely solid — NAD+ levels really do decline with age, and that decline really is implicated in mitochondrial dysfunction. What has not been established is that raising NAD+ in a human reverses any of it.
Human trials of NAD+ precursors have been small and short, have generally shown that blood NAD+ can be raised, and have largely failed to demonstrate the downstream clinical benefits the marketing promises. This is the purest example on the site of biomarker-for-outcome substitution: a real biological change being sold as a health outcome it has not been shown to produce.
Cost
Publishing an unverified number would be worse than publishing none. When we have captured them, they will appear here with a source and a verification date, exactly like our GLP-1 pricing.
How to evaluate any quote you are given
Since we will not hand you a number we cannot stand behind, the useful thing we can give you is the method. Every quote in this category should be normalised the same way we normalise GLP-1 pricing.
| Ask for… | Because… |
|---|---|
| The total monthly cost, including every fee | Split billing — medication plus a membership — is the commonest way a price looks lower than it is |
| The ongoing price, not the first month | Introductory rates are customer-acquisition pricing. You pay the ongoing rate for eleven of twelve months |
| Whether the price rises with dose | A programme that is cheapest at the starting dose can be the most expensive at maintenance |
| What happens if you cancel early | On a committed plan this is the question most likely to cost you money, and the one most often skipped |
| Whether labs, shipping and visits are included | 'All-inclusive' is used loosely. Test it against specifics rather than accepting the phrase |
| The annual total | Monthly figures are how this is marketed. Annual totals are how it is actually experienced |
Why we publish no number here, when every competitor does
Search this treatment and you will find a dozen pages confidently quoting a monthly price. We could do the same in five minutes. We have not, and the reason is worth stating because it is the whole difference between this site and those.
A price is a claim about the world. To publish one responsibly you need to have captured it — from the provider's own page, on a stated date, with the fee structure, the commitment, the dose ceiling and the cancellation terms attached. Anything less is repetition, and repetition is how the contradictory figures in this industry propagate: one site guesses, three copy it, and by the fourth it reads as consensus.
We have captured that evidence for GLP-1 pricing, which is why our GLP-1 pages carry dated figures and evidence labels. We have not captured it for this treatment. So we publish the method for evaluating a quote instead of a number we cannot defend — and when we do capture it, it will appear here with a source and a date.
We do not mark a price Verified merely because another comparison site published it. Sites in this category contradict each other routinely. A number repeated by three comparison blogs is still one unverified number.
Questions to ask before you pay
Questions to ask about the pharmacy
The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.
- Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
- Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
- In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
- What is the exact substance, salt form and concentration? Get it in writing, and check the substance’s status on our peptide status table.
- Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
- Will you provide a certificate of analysis?
- Has the pharmacy received any FDA warning letter or state board action?
A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.
The context that applies to this whole category
Three patterns recur across peptide and longevity marketing, and once you can name them you will see them everywhere.
Mouse-to-human transfer. A striking longevity or fat-loss result in mice is presented as though it applies to you. Mouse longevity findings have a long and well-documented history of not translating to humans.
Biomarker-for-outcome substitution. A study shows a blood level rose — NAD+, IGF-1, growth hormone — and the marketing implies you will therefore feel better, look better or live longer. Raising a biomarker is not the same as improving an outcome, and for most of these treatments the outcome studies simply have not been done.
Deficiency-to-enhancement transfer. A treatment that genuinely helps people with a diagnosed deficiency is sold to healthy people seeking optimisation. Tesamorelin works for HIV-associated lipodystrophy; that is not evidence that it works for a healthy 45-year-old who wants a flatter stomach.
None of these are valid inferences. All three are standard in this industry's marketing.
Frequently asked questions
What does NAD+ therapy cost?
We have not verified a market price. On October 15, 2026, Oak Longevity listed NAD+ injections at $175 a month, regularly $199, a promotional price. That is one provider’s page, not a typical price. Ask any clinic for the total cost per month, including visits and supplies, in writing.
Is NAD+ therapy covered by insurance?
Generally not. Compounded peptides and NAD+ are not FDA-approved for the uses they are marketed for, and insurers do not typically cover them. Expect to pay cash.
How do I evaluate a quote?
Ask for the total monthly cost including every fee; whether the price rises with dose; what happens if you cancel; which pharmacy compounds it; and what the concentration is. A provider who will not answer in writing has told you something.
Sources
- U.S. Food and Drug Administration — approved labels and compounding guidance.
- PubMed / NIH — indexed clinical literature for this molecule.
- ClinicalTrials.gov — registered trials, where they exist.
- Our pricing-verification methodology.
- We do not cite other comparison sites as evidence of price — see our source hierarchy.